@NatalieJLambert@medrxivpreprint "Symptoms causing greatest distress (scale 1 “none” to 5 “great deal”) were extreme pressure at base of head (4.4), syncope (4.3), sharp or sudden chest pain (4.2), brain pressure (4.2), headache (4.2), persistent chest pain or pressure (4.1), and bone pain in extremities (4.1)."
@NatalieJLambert@medrxivpreprint Again, we see a remarkable range of downstream symptoms from COVID; this illness has devastating consequences for so many that extends far beyond the acute illness. Much to learn. Need to move quickly. @Survivor_Corps@dianaberrent
Worth your time to take a look at @EdwardTufte new book: Seeing with Fresh Eyes: Meaning, Space, Data, Truth. He is a visionary warrior fighting for clarity in visual communication. Has always inspired me. edwardtufte.com/tufte/seeing-w…
@EdwardTufte From @EdwardTufte: “Conventions (We’ve always done it this way) enshired in leagacy code caused 50 years of content-hostile and reader-inconvenient data graphics in powerpoint, excel, and sophisticated data-analysis computer packages."
@EdwardTufte From @EdwardTufte: ‘Electronic health records seize ownership of medical information. Medical center business plans = own the data, own the patient.’ ‘Medical centers…intimidate patients to sign gag orders seizing ownership of all records.' @ePatientDave@TheLizArmy@myopennotes
Very interested in @Regeneron therapy…2 non-competing neutralizing antibodies…one to receptor binding domain of the spike protein and one to the ACE receptor. They reported out early interim results for treatment of symptomatic people. Other studies pending
@Regeneron Inclusion criteria for the @Regeneron study was adult, non-hospitalized, symptoms <=7d, SARS-CoV-2 confirmed, and not on other COVID-19 therapies. Mean age was 44y. Half male. 42% obese. 7% (20 people) in the reported group were 65y and older.
@Regeneron The antibody cocktail to SARS-CoV-2 had a greater reduction in viral load for those whose viral load was higher at baseline.
On the #COVID19 transparency front: JNJ has announced that they will share the Clinical Study Report and clinical trial participant data from their vaccine trial with researchers through @Yale Open Data Access (YODA) Project. @YaleMed@jsross119@JNJNewsjnj.com/coronavirus/le…
@Yale@YaleMed@jsross119@JNJNews To provide context for the JNJ vaccine data sharing, @Yale YODA Project provides access to data to researchers w/ credible scientific proposal, agreement to report results, & commitment to protect participant privacy. Access decision is independent. yoda.yale.edu
@Yale@YaleMed@jsross119@JNJNews To date, @Yale Open Data Access (YODA) Project has resulted in 42 submitted publications (31 published) based on JNJ participant-level data sharing. JNJ (Janssen) has committed to sharing data from all their drug and device trials through the YODA project. jnj.com/coronavirus/ou…
@davidbeier1747@LawrenceGostin@TomBollyky The authors 'We argue that two concrete policy steps could go a long way toward establishing public trust in COVID-19 vaccines:full and public disclosure of all data used to justify approval of a vaccine, and the creation of an independent and bipartisan committee to advise FDA.'
@davidbeier1747@LawrenceGostin@TomBollyky They go on to say: 'We believe that the last chapter of this steeplechase will be whether enough people get vaccinated. Current and expected levels of vaccine hesitancy are far too high to end the pandemic.’